New insights into molecular mechanisms responsible for cellular radiation response are coming from recent basic radiobiological studies. Preliminary data supporting the concept of clinical radiosensitivity as a complex genetically controlled event are available, and it seems reasonable to hypothesize that genes encoding for proteins implicated in known radiation-induced pathways, such as DNA repair, could influence normal tissue and tumor response to radiotherapy. Such genes could be considered as candidates for experimental studies and as targets for innovative therapies. Variants that could influence individual radiosensitivity have been recently identified, and specific Single Nucleotide Polymorphisms have been associated to the development of different radiation effects on normal tissues. Allelic architecture of complex traits able to modify phenotypes is difficult to be established, and different grades of interaction between common or rare genetic determinants may be present and should be considered. Many different experimental strategies could be investigated in the future, such as analysis of multiple genes in large irradiated patient cohorts strictly observed for radiation effects or identification of new candidate genes, with the aim of identifying factors that could be employed in predictive testing and individualization of radiation therapy on a genetic basis.
AlterB.P.: Radiosensitivity in Fanconi's anemia patients.Radiother Oncol,62: 345–347, 2002.
2.
RogersP.B., PlowmanP.N., HarrisS.J., ArlettC.F.: Four radiation hypersensitivity cases and their implications for clinical radiotherapy.Radiother Oncol,57: 143–154, 2000.
3.
GattiR.A.: The inherited basis of human radiosensitivity.Acta Oncol,40: 702–711, 2001.
4.
RiballoE., CritchlowS.E., TeoS.H., DohertyA.J., PriestleyA., BroughtonB., KyselaB., BeamishH., PlowmanP.N., ArlettC.F., LehmannA.R., JacksonS.P., JeggoP.A.: Identification of a defect in DNA ligase IV in a radiosensitive leukemia patient.Curr Biol,9: 699–702, 1999.
5.
SeverinD.M., LeongT., CassidyB., ElsalehH., PetersL., VenterD., SoutheyM., McKayM.: Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients.Int J Radiat Oncol Biol Phys,50: 1323–1331, 2001.
AndreassenC.N., AlsnerJ., OvergaardJ.: Does variability in normal tissue reactions after radiotherapy have a genetic basis – where and how to look for it?Radiother Oncol,64: 131–140, 2002.
8.
BarberJ.B., BurrillW., SpreadboroughA.R., LevineE., WarrenC., KiltneA.E., RobertsS.A., ScottD.: Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer.Radiother Oncol,55: 179–186, 2000.
9.
BudachW., ClassenJ., BelkaC., BambergM.: Clinical impact of predictive assays for acute and late radiation morbidity.Strahlenther Onkol,174: 20–24, 1998.
10.
BurrillW., BarberJ.B., RobertsS.A., BulmanB., ScottD.: Heri-tability of chromosomal radiosensitivity in breast cancer patients: a pilot study with the lymphocytes micronucleus assay.Int J Radiat Biol,76: 1617–1619, 2000.
11.
RobertsS.A., SpreadboroughA.R., BulmanB., BarberJ.B., EvansD.G., ScottD.: Heritability of cellular radiosensitivity: a marker of low penetrance predisposition genes in breast cancer?Am J Hum Genet,65: 784–794, 1999.
12.
DikomeyE., BorgmannJ., PeacockJ., JungH.: Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed.Int J Radiat Oncol Biol Phys,56: 1192–1200, 2003.
13.
TwardellaD., Chang-ClaudeJ.: Studies on radiosensitivity from an epidemiological point of view - overview of methods and results.Radiother Oncol,62: 249–260, 2002.
14.
Mariano Ruiz de AlmodovarJ., GuiradoD., Isabel NunezM., LopezE., GuerrieroR., Teresa ValenzuelaM., VillalobosM., del MoralR.: Individualization of radiotherapy in breast cancer patients: possible usefulness of a DNA damage assay to measure normal cell radiosensitivity.Radiother Oncol,62: 327–333, 2002.
15.
TellR., EdgrenM.R., SverrisdottirA., CastroJ., FornanderT., HanssonL.O., SkogS., LewensohnR.: Radiation induced cell cycle response in lymphocytes is not related to clinical side effects in breast cancer patients.Anticancer Res,23: 3077–3083, 2003.
16.
MeynM.S.: Ataxia Teleangiectasia, cancer and the pathobiolo-gy of the ATM gene.Clin Genet,55: 289–304, 1999.
17.
WeissbergJ.B., HuangD.D., SwiftM.: Radiosensitivity of normal tissues in ataxia telangiectasia heterozygotes.Int J Radiat Oncol Biol Phys,42: 1133–1136, 1998.
18.
ApplebyJ.M., BarberJ.B., LevineE.: Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy.Br J Cancer,76: 1546–1549, 1997.
19.
ClarkeR.A., GoozeG.R., BirrellG., FangZ.M., HasnainH., LavinM., KearsleyJ.K.: Absence of ATM truncations in patients with severe acute radiation reactions.Int J Radiat Oncol Biol Phys,41: 1021–1027, 1998.
20.
OppitzU., BernthalerU., SchindlerD.: Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late effects.Int J Radiat Oncol Biol Phys,44: 981–988, 1999.
21.
RamsayJ., BirrellG., LavinM.: Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients.Radiother Oncol,47: 125–128, 1998.
22.
ShayeghiM., SealS., ReganJ., CollinsN., BarfootR., RahamanN., AshtonA., MoohanM., WoosterR., OwenR., BlissJ.M., StrattonM.R., YarnoldJ.: Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients.Br J Cancer,78: 922–927, 1998.
23.
IannuzziC.M., AtencioD.P., GreenS.: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects.Int J Radiat Oncol Biol Phys,52: 606–613, 2002.
24.
AngeleS., RomestaingP., MoullanN., VuillaumeM., ChapotB., FriesenM., JongmansW., CoxD.G., PisaniP., GerardJ.P., HallJ.: ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity.Cancer Res,63: 8717–8725, 2003.
25.
BucholtzT.A., WuX., HussainA., TuckerS.L., MillsG.B., HafftyB., BerghS., StoryM., GearaF.B., BrockW.A.: Evidence of hap-lotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2.Int J Cancer,97: 557–561, 2002.
26.
XiaF., PowellS.N.: The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer.Semin Radiat Oncol,12: 296–304, 2002.
27.
HofmannW., SchlagP.M.: BRCA1-BRCA2 breast cancer susceptibility genes.J Cancer Res Clin Oncol,126: 487–496, 2000.
28.
LeongT., WhittyJ., KeilarM., MifurdS., RamsayJ., BirrelG., VenterD., SoutheyM., McKayM.: Mutation analysis of BR-CA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.Int J Radiat Oncol Biol Phys,48: 959–965, 2000.
29.
MarcouY., D'AndreaA., JeggoP.A., PlowmanP.N.: Normal cellular radiosensitivity in an adult Fanconi's anemia patient with marked clinical radiosensitivity.Radiother Oncol,60: 75–79, 2001.
30.
PriceE.A., BourneS.L., RadbourneR., LawtonP.A., LomerdinJ., ThompsonL.H., ArrandJ.E.: Rare microsatellite polymorphism in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity.So-mat Cell Mol Genet,23: 237–247, 1997.
31.
ThompsonL.H., WestM.G.: XRCC1 keeps DNA from getting stranded.Mutat Res,459: 1–18, 2000.
32.
MoullanN., CoxD.G., AngeleS., RomestaingP., GerardJ.P., HallJ.: Polymorphisms in the DNA repair gene XRCC1, breast cancer risk and response to radiotherapy.Cancer Epidemiol Biomarkers Prev,12: 1168–1174, 2003.
33.
WangY., SpitzM.R., ZhuY., DongQ., SheteS., WuX.: From genotype to phenotype: correlating XRCC1 polymorphism with mutagen sensitivity.DNA Repair,2: 901–908, 2003.
34.
AndreassenC.N., AlsnerJ., OvergaardM., OvergaardJ.: Prediction of normal tissue radiosensitivity from polymorphism in candidate genes.Radiother Oncol,69: 127–135, 2003.
35.
QuarnbyS., FakhouryH., LevineE., BarberJ., WylieJ., HajeerA.H., WestC., StewartA.L., MageeB., KumarS.: Association of transforming growth factor beta-1 single nucleotide polymorphism with radiation-induced damage to normal tissue in breast cancer patients.Int J Radiat Biol,79: 137–143, 2003.
36.
LiC., WilsonP.B., LevineE., BarberJ., StewartA.L., KumarS.: TGF-beta 1 levels in pretreatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis.Int J Cancer,84: 155–159, 1999.
37.
GreenH., RossG., PeacockJ., OwenR., YarnoldJ., HoulstonR.: Variation in the manganese superoxyde dismutase gene SOD2 is not a major cause of radiotherapy complications in breast cancer.Radiother Oncol,63: 213–216, 2002.
De MurciaG., MenissierD.M.: Poly (ADPribose) polymerase: a molecular nick-sensor.Trend Biochem Sci,19: 172–176, 1994.
40.
JeggoP.A.: DNA repair: PARP – another guardian angel?Curr Biol,8: 49–51, 1998.
41.
RudatV., KupperJ.H., WeberK.J.: Trans-dominant inhibition of poly (ADP-ribosylation) leads to decreased recovery from ionizing radiation cell killing.Int J Radiat Oncol Biol Phys,73: 325–330, 1998.
42.
BristowR.G., JangA., PeacockJ., ChungS., BenchimolS., HillR.P.: Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-Eqn 7 and/or activates H-ras.Oncogene,9: 1527–1536, 1994.
43.
YangY.M., DolanL.R., RonaiZ.: Expression of dominant CREB reduces resistance to radiation of human melanoma cells.Oncogene,12: 2223–2233, 1996.
44.
HallahanD.E., DunphyE., Viriduchalam, SukhatmeV.P., KufeD.W., WeichselbaumR.R.: C-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure.J Biol Chem,270: 30303–30309, 1995.
45.
UhrammerN., FritzE., BoydenC., MeynM.S.: Human fibroblasts transfected with an antisense vector respond abnormally to ionizing radiation.Int J Mol Med,4: 43–47, 1999.
46.
ZhangN., ChenP., GateiM., ScottS., KhannaK., LavinM.F.: An antisense construct of full-length ATM cDNA imposes a radiosensitivity phenotype on normal cells.Oncogene,17: 811–818, 1998.
47.
EssersJ., HendricksR.W., SwagemakersS.M., TroelstraC., de WitJ., BootsmaD., HoeijmakersJ.H., KanaarR.: Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination.Cell,89: 195–204, 1997.
48.
OhnishiT., TakiT., HiragaS., AritaN., MoritaT.: In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the rad51 gene.Biochem Biophys Res Commun,245: 319–324, 1998.
GhadimiB.M., GradeM., DifilippantonioM.J., VarmaS., SimonR., MontagnaC., FuzesiL., LangerC., BeckerH., LierschT., RiedT.: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.J Clin Oncol,23: 1826–1832, 2005.
51.
KitaharaO., KatagiriT., TsunodaT., HarimaY., NakamuraY.: Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis.Neoplasia,4: 295–303, 2004.
